MESO has been approved to sell remestemcel-l (labeled TEMCELL by partner JCR Pharmaceuticals) for acute Graft vs Host disease (aGVHD) in Japan for several years. Prior to the pandemic, MESO was on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback